Evidence map›Paper›PMID 42855459›Full record

ArticleCell death discovery2026

C2ORF68 stabilizes SIVA1 to upregulate BCL-2 and suppress apoptosis in gallbladder cancer.

Xuanjia Dong, Lingxiao Zhang, Wenjun Dong, Qiuyi Tang, Jingwei Zhao, Zhaohui Jin, Lin Jiang, Wenting Dai, Yangyang Zhai, Ying Huang

Abstract read
PubMed Publisher
In one paragraph

Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xuanjia Dong *Shanghai Key Laboratory of Biliary Tract Disease Research, Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Lingxiao Zhang *Shanghai Key Laboratory of Biliary Tract Disease Research, Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Wenjun DongShanghai Key Laboratory of Biliary Tract Disease Research, Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Qiuyi TangShanghai Key Laboratory of Biliary Tract Disease Research, Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Jingwei ZhaoShanghai Key Laboratory of Biliary Tract Disease Research, Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Zhaohui JinShanghai Key Laboratory of Biliary Tract Disease Research, Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Lin JiangShanghai Key Laboratory of Biliary Tract Disease Research, Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Wenting DaiShanghai Key Laboratory of Biliary Tract Disease Research, Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Yangyang ZhaiShanghai Key Laboratory of Biliary Tract Disease Research, Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China. yyzhai015@sjtu.edu.cn.ORCID http://orcid.org/0009-0002-3853-5126
Ying HuangShanghai Key Laboratory of Biliary Tract Disease Research, Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China. huangy@shsmu.edu.cn.ORCID http://orcid.org/0000-0002-2806-2874

Funding

National Natural Science Foundation of China (National Science Foundation of China) 32571493National Natural Science Foundation of China (National Science Foundation of China) 82403671
6 · The paper itself

Abstract

Gallbladder cancer (GBC) is the most aggressive malignancy of the biliary tract, and its molecular drivers remain insufficiently understood. SIVA1 (apoptosis regulatory protein Siva 1) has been implicated in the regulation of cell survival, but its function in GBC has not been defined. In this study, we found that SIVA1 expression was elevated in GBC tissues and cell lines, and high SIVA1 expression was associated with poor patient prognosis. Gain- and loss-of-function experiments demonstrated that SIVA1 promoted GBC cell proliferation and migration in vitro and facilitated tumor growth in nude mice xenograft model. Mechanistically, SIVA1 was subject to ubiquitin-proteasome-mediated degradation, and we identified C2ORF68 as a binding partner that reduced SIVA1 ubiquitination and stabilized its protein level. Stabilized SIVA1 in turn increased the expression of the anti-apoptotic protein BCL-2, thereby enhancing cell survival. These findings indicate that C2ORF68-mediated stabilization of SIVA1 promotes GBC progression through BCL-2-dependent anti-apoptotic signaling, supporting SIVA1 as a potential therapeutic target.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.